RHEUMATIC DISEASES AND TUBERCULOSIS INFECTION IN CHILDREN AND ADULTS
https://doi.org/10.21292/2075-1230-2019-97-2-50-55
Abstract
The authors summarized publications on the risk to develop tuberculosis during the treatment of rheumatic diseases with genetically engineered biologic drugs. The article describes the approaches to optimization of tuberculosis control activities in patients with rheumatic diseases: immunodiagnostics of latent tuberculosis infection and prevention of tuberculosis disease in the patients receiving genetically engineered biological drugs.
About the Authors
G. V. Santalova
Samara State Medical University
Russian Federation
Russian Federation
Galina V. Santalova Doctor of Medical Sciences, Professor, Head of Faculty Pediatrics Department.
89, Chapaevskaya St., Samara, 443099
E. A. Borodulina
Samara State Medical University
Russian Federation
Russian Federation
Elena A. Borodulina Doctor of Medical Sciences, Professor, Head of Phthisiology and Pulmonology Department.
89, Chapaevskaya St., Samara, 443099
D. A. Kudlay
Immunology Research Institute by the Russian Federal Medical Biological Agency
Russian Federation
Russian Federation
Dmitry A. Kudlay Doctor of Medical Sciences, Professor of Healthcare Economy and Marketing Department.
24, Kashirskoye Highway, Moscow, 115552
D. S. Badaeva
Samara State Medical University
Russian Federation
Russian Federation
Darya S. Badaeva Resident of the 1st Year of Training of Faculty Pediatrics Department.
89, Chapaevskaya St., Samara, 443099
B. E. Borodulin
Samara State Medical University
Russian Federation
Russian Federation
Boris E. Borodulin Doctor of Medical Sciences, Professor of Phthisiology and Pulmonology Department.
89, Chapaevskaya St., Samara, 443099
E. S. Gasilina
Samara State Medical University
Russian Federation
Russian Federation
Elena S. Gasilina Doctor of Medical Sciences, Professor, Head of Children Infections Department.
89, Chapaevskaya St., Samara, 443099
References
1. Аksenov M.V., Pyatykh E.А. Potential use of genetically engineered biologic drugs for the treatment of rheumatoid arthritis. Mezhdunarodny Studencheskiy Nauchny Vestnik, 2015, no. 2-3, pp. 396-398. (In Russ.)
2. Аlekseeva E.I., Bzarova T.M. Procedure for diagnostics and treatment of juvenile arthritis. Voprosy Sovremennoy Pediatrii, 2010, no. 9 (6), pp. 78-104. (In Russ.)
3. Аlekseeva E.I., Bzarova T.M. Juvenile arthritis: possibilities of medicamentous and non-medicamentous treatment at the modern stage. Lechaschy Vrach, 2011, no. 8, pp. 4-89. (In Russ.)
4. Baranov А.А., Аlekseeva E.I. Detskaya revmatologiya. Yuvenilny artrit: klinicheskie rekomendatsii dlya pediatrov. [Children rheumatology. Juvenile arthritis: clinical recommendations for pediatricians]. Moscow, Pediatr Publ., 2013, 120 p.
5. Baranov А.А., Аlekseeva E.I., Valieva S.I., Bzarova T.M., Denisova R.V., Chistyakova E.G. Biological therapy in pediatric rheumatology. Voprosy Sovremennoy Pediatrii, 2011, no. 1, pp. 5-16. (In Russ.)
6. Belov B.S. Therapy with genetically engineering biologic drugs and infections in patients with rheumatoid arthritis: relevance and prospects. Nauchno-Prakticheskaya Revmatologiya, 2014, no. 52 (3), pp. 322-330. (In Russ.)
7. Borisov S.E., Lukina G.V., Slogotskaya L.V. Screening and monitoring of tuberculous infection in rheumatologic patients, treated by genetically engineered biological agents. Tuberculosis and Lung Diseases, 2011, no. 6, pp. 42-50. (In Russ.)
8. Borodulina E.А. Screening for tuberculosis infection. Contemporary recommendations. Аllergologiya i Immunologiya v Pediatrii, 2017, no. 2 (49), pp. 29-33.
9. Vakhlyarskaya S.S. Аnaliz effektivnosti antagonista nekroza opukholey (adalimumaba) i mofetilamikofenolata v kompleksnoy terapii yuvenilnogo revmatoidnogo artrita. Diss. kand. med. nauk. [Analysis of the tumor necrosis antagonist (adalimumab) and mycophenolatis mofetilum efficacy in the comprehensive treatment of juvenile rheumatoid arthritis. Cand. Diss.]. Moscow, 2014, 161 p.
10. Volchkova I.L., Spivakovskiy Yu.M., Kazimirova N.E., Pankratova L.E. Differentiated approach to preventive treatment of children and adolescents infected with tuberculosis and suffering from juvenile rheumatoid arthritis. Tuberculosis and Lung Diseases, 2015, no. 5, pp. 65-66. (In Russ.)
11. Geppe N.А., Podchernyaeva N.S., Lyskina G.А. Rukovodstvo po detskoy revmatologii. [Children rheumatology guidelines]. Moscow, GEOTAR-Media Publ., 2011, 720 p.
12. Davydova M.А. Development and prognosis of destructive joint changes in children with juvenile idiopathic arthritis. Voprosy Prakticheskoy Pediatrii, 2017, no. 12 (3), pp. 46-53. (In Russ.)
13. Davydova M.А., Santalova G.V., Stadler E.R., Gasilina E.S. Dynamics in destructive changes of joints in case of juvenile idiopathic arthritis in children who received methotrexate or a combination of methotrexate and tocilizumab: a cohort study. Voprosy Sovremennoy Pediatrii, 2017, no. 16 (6), pp. 502-508. (In Russ.)
14. Zholobova E.S. The systemic form of juvenile idiopathic arthritis (diagnosis and treatment). RMJ, 2012, no. 30, pp. 1514. (In Russ.)
15. Zholobova E.S., Konopelko O.Yu., Rozvadovskaya O.S., Elyashevich V.Ya., Nikolaeva M.N. Etanercept in the real clinical practice when treating patients with active juvenile idiopathic arthritis. Nauchno-Prakticheskaya Revmatologiya, 2013, no. 51 (1), pp. 44-47. (In Russ.)
16. Mikheeva I.V., Burdova E.Yu., Melnikova А.А. Comparative evaluation of allergen diagnostics of tuberculosis in children. Epidemiologiya i Vaktsionoprofilaktika, 2016, no. 15 (3), pp. 41-44. (In Russ.)
17. Nasonov E.L., Kozlov R.S., Yakushin S.B. Infectious complications of therapy with tumor necrosis factor blockers: forewarned is forearmed. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2006, no. 4, pp. 1-11. (In Russ.)
18. Neroev V.V., Katargina L.А., Denisova E.V., Starikova А.V., Lyubimova N.V. The effectiveness of genetic engineering biological agents in the treatment of uveitis associated with rheumatic diseases in children. Nauchno-Prakticheskaya Revmatologiya, 2012, no. 53 (4), pp. 91-95. (In Russ.)
19. Teschenkov А.V., Shumilov P.V., Myakisheva T.V., Аvdeeva T.G. The development and course of latent tuberculosis infection in children with rheumatoid arthritis. Vestnik Smolenskoy Gosudarstvennoy Meditsinskoy Akademii, 2016, no. 15 (4), pp. 64-71. (In Russ.)
20. Chichasova N.V., Nasonov E.L. The safety of using genetically engineering biologic drugs for treatment of rheumatoid arthritis. Sovremennaya Revmatologiya, 2010, no. 1 (10), pp. 46-58. (In Russ.)
21. Shilova T.V., Pischalnikov А.Yu., Volosnikov D.K., Kolyadina N.А. The value of distribution of HLA class I antigens in children with juvenile idiopathic arthritis. Pediatricheskiy Vestnik Yuzhnogo Urala, 2013, no. 2, pp. 126-128. (In Russ.)
22. Schadneva S.I. Genetically engineered biologic drugs in the treatment of rheumatic diseases. Zabaykalskiy Meditsinskiy Journal, 2016, no. 2, pp. 3-8. (In Russ.)
23. Alexeeva E.I., Valieva S.I., Bzarova T.M., Semikina E.L., Isaeva K.B., Lisitsyn A.O. et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clinical Rheumatology, 2011, no. 30, pp. 1163-1172.
24. Angeleshan S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis associated uveitis ‒ a case report. Intern. J. Clin. Rheumatology, 2008, no. 35 (9), pp. 1897-1898.
25. Burst D., Keystone E., Kirkham B., Breedveld F., Burmester G., De Benedetti F. Update consensus statement on biological agents for the treatment of rheumatic diseases. Ann. Rheumatic Diseases, 2008, no. 67, pp. 2-25.
26. Dixon W.G., Hyrich K.L., Watson K.D. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheumatic Diseases, 2010, no. 69 (3), pp. 522-528.
27. Furst D.E., Breedveld F.C., Kalden J.R. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases 2005. Annals of the Rheumatic Diseases, 2005, no. 64 (4), pp. 2-14.
28. Gomez-Reino J.J., Carmona L., Valverde V.R. BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis & Rheumatology, 2003, no. 48 (8), pp. 2122-2127.
29. Hayward K., Wallace C. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Research & Therapy, 2009, no. 11, pp. 216.
30. Horneff G. Treatment options with biologics for juvenile idiopathic arthritis. Intern. J. Clinical Rheumatology, 2011, no. 6 (3), pp. 1-19.
31. Keane J., Gershon S., Wise R.P. Tuberculosis associated with infliximab, a tumor necrosis factor alpha–neutralizing agent. New Eng. J. Medicine., 2001, no. 345 (15), pp. 1098-1104.
32. Kroesen S., Widmer A.F., Tyndall A., Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology, 2003, no. 42, pp. 617-621.
33. Marie I., Hachulla E., Cherin P., Hellot M.-F., Herson S., Levesque H. Opportunistic infections in polymyositis and dermatomyositis. Arthritis & Rheumatology, 2005, no. 53 (2), pp. 155-165.
34. Parra R.J., Ortego C.N., Raya Alvarez E. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. Intern. J. Clin. Rheumatology, 2003, no. 30, pp. 1657-1658.
35. Saay K., Тепу G., Patkar X. Recommendations for Lite use of nonbiologic and biologic disease-modifying antirheumatic drug' in rheumatoid arihrius. Arthr. Care Research, 2018, no. 59, pp. 762-781.
36. Shovkun L., Aksenova V., Kudlay D., Sarichev A. The role of immunological tests in the diagnosis of tuberculosis infection in children with juvenile idiopathic arthritis (JIA). Eur. Respir. J., 2018, vol. 52, suppl. 62. pp. A2733.
37. Slogotskaya L.V., Bogorodskaya E., Sentchichina O., Ivanova D., Nikitina G., Litvinov V., Seltsovsky, P., Kudlay D.A., Nikolenko N., Borisov S. Effectiveness of tuberculosis detection using a skin test with allergen recombinant (CFP-10-ESAT-6) in children. Eur. Respir. J., 2015, vol. 46, no. S59, pp. А4524.
38. Slogotskaya L.V., Bogorodskaya Е., Ivanova D., Makarova, M., Guntupova L., Litvinov, V., Seltsovsky P., Kudlay D.A., Nikolenko N. Sensitivity and specificity of new skin test with recombinant protein CFP10-ESAT6 in patients with tuberculosis and individuals with non- tuberculosis diseases. Eur. Respir. J., 2013, vol. 42, no. S57, pp. 1995.
39. Slogotskaya L.V., Litvinov V., Ovsyankina E., Seltsovsky P., Kudlay D. Results of QuantiFERON-TB Gold in-tube and skin testing with recombinant proteins CFP-10-ESAT-6 in children and adolescents with TB or latent TB infection. Paediatric Respiratory Reviews, 2013, vol. 14, no. 2, pp. S65.
40. Smolen J.S., Landewé R., Bijlsma J., Burmester G., Chatzidionysiou K., Dougados M. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheumatic Diseases, 2017, no. 76 (6), pp. 960-977.
41. Tubach F., Salmon D., Ravaud P. Research Axedon Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French research axed on tolerance of biotherapies registry. Arthritis & Rheumatology, 2009, no. 60 (7), pp. 1884-1894.
Review
For citations:
Santalova G.V., Borodulina E.A., Kudlay D.A., Badaeva D.S., Borodulin B.E., Gasilina E.S. RHEUMATIC DISEASES AND TUBERCULOSIS INFECTION IN CHILDREN AND ADULTS. Tuberculosis and Lung Diseases. 2019;97(2):50-55. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-2-50-55
Views:
2661
Email this article 